FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
about
Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.Combined use of preoperative lymphocyte counts and the post/preoperative lymphocyte count ratio as a prognostic marker of recurrence after curative resection of stage II colon cancer.Evaluation of appropriate follow-up after curative surgery for patients with colorectal cancer using time to recurrence and survival after recurrence: a retrospective multicenter study.BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)Transplantation for colorectal metastases: on the edge of a revolution
P2860
FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
FOLFOXIRI Plus Bevacizumab as ...... ic Review and Pooled Analysis.
@en
type
label
FOLFOXIRI Plus Bevacizumab as ...... ic Review and Pooled Analysis.
@en
prefLabel
FOLFOXIRI Plus Bevacizumab as ...... ic Review and Pooled Analysis.
@en
P2093
P2860
P1433
P1476
FOLFOXIRI Plus Bevacizumab as ...... ic Review and Pooled Analysis.
@en
P2093
Alessandro Russo
Fausto Petrelli
Gianluca Tomasello
Michele Ghidini
Rodolfo Passalacqua
Sandro Barni
P2860
P304
P356
10.1001/JAMAONCOL.2017.0278
P577
2017-07-13T00:00:00Z